{"pmid":32425698,"pmcid":"PMC7229742","title":"Will Colombian intensive care units collapse due to the COVID-19 pandemic?","text":["Will Colombian intensive care units collapse due to the COVID-19 pandemic?","Travel Med Infect Dis","Diaz-Guio, Diego Andres","Villamil-Gomez, Wilmer E","Dajud, Luis","Perez-Diaz, Carlos E","Bonilla-Aldana, D Katterine","Mondragon-Cardona, Alvaro","Cardona-Ospina, Jaime A","Gomez, Jose F","Rodriguez-Morales, Alfonso J","32425698"],"journal":"Travel Med Infect Dis","authors":["Diaz-Guio, Diego Andres","Villamil-Gomez, Wilmer E","Dajud, Luis","Perez-Diaz, Carlos E","Bonilla-Aldana, D Katterine","Mondragon-Cardona, Alvaro","Cardona-Ospina, Jaime A","Gomez, Jose F","Rodriguez-Morales, Alfonso J"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425698","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.tmaid.2020.101746","keywords":["covid-19","colombia","critical care","intensive care units","sars-cov-2"],"weight":0,"_version_":1667352728735580160,"score":9.490897,"similar":[{"pmid":32324428,"title":"The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States.","text":["The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States.","With the coronavirus disease 2019 (COVID-19) pandemic, one of the major concerns is the burden COVID-19 will impose on the United States (U.S.) health care system. We developed a Monte Carlo simulation model representing the U.S. population and what can happen to each person who gets infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). We estimate resource use and direct medical costs per infection and at the national level, with various \"attack rates\" (infection rates) to understand the potential economic benefits of reducing the burden of the disease. A single symptomatic COVID-19 infection would cost a median of $3,045 in direct medical costs incurred only during the course of the infection. Eighty percent of the U.S. population getting infected could result in a median of 44.6 million hospitalizations, 10.7 million ICU admissions, 6.5 million ventilators used, and 249.5 million hospital bed days, costing $654.0 billion in direct costs over the course of the pandemic. If 20% were to become infected, there would be a median of 11.2 million hospitalizations, 62.3 million hospital bed days, and 1.6 million ventilators used, costing $163.4 billion. [Editor's Note: This fast-track Ahead-of-Print article is the accepted version of the peer-reviewed manuscript. The final edited version will appear in an upcoming issue of Health Affairs.].","Health Aff (Millwood)","Bartsch, Sarah M","Ferguson, Marie C","McKinnell, James A","O'Shea, Kelly J","Wedlock, Patrick T","Siegmund, Sheryl S","Lee, Bruce Y","32324428"],"abstract":["With the coronavirus disease 2019 (COVID-19) pandemic, one of the major concerns is the burden COVID-19 will impose on the United States (U.S.) health care system. We developed a Monte Carlo simulation model representing the U.S. population and what can happen to each person who gets infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). We estimate resource use and direct medical costs per infection and at the national level, with various \"attack rates\" (infection rates) to understand the potential economic benefits of reducing the burden of the disease. A single symptomatic COVID-19 infection would cost a median of $3,045 in direct medical costs incurred only during the course of the infection. Eighty percent of the U.S. population getting infected could result in a median of 44.6 million hospitalizations, 10.7 million ICU admissions, 6.5 million ventilators used, and 249.5 million hospital bed days, costing $654.0 billion in direct costs over the course of the pandemic. If 20% were to become infected, there would be a median of 11.2 million hospitalizations, 62.3 million hospital bed days, and 1.6 million ventilators used, costing $163.4 billion. [Editor's Note: This fast-track Ahead-of-Print article is the accepted version of the peer-reviewed manuscript. The final edited version will appear in an upcoming issue of Health Affairs.]."],"journal":"Health Aff (Millwood)","authors":["Bartsch, Sarah M","Ferguson, Marie C","McKinnell, James A","O'Shea, Kelly J","Wedlock, Patrick T","Siegmund, Sheryl S","Lee, Bruce Y"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324428","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1377/hlthaff.2020.00426","keywords":["coronavirus","covid-19","cost reduction","costs and spending","diseases","economic burden","hospital costs","intensive care units","prescription drug costs","value","cost","health policy"],"locations":["United States","USA","USA","USA","United States"],"countries":["United States"],"countries_codes":["USA|United States"],"weight":0,"_version_":1666138493832658946,"score":58.10198},{"pmid":32393325,"title":"Preparing your intensive care unit for the COVID-19 pandemic: practical considerations and strategies.","text":["Preparing your intensive care unit for the COVID-19 pandemic: practical considerations and strategies.","The coronavirus disease 2019 (COVID-19) has rapidly evolved into a worldwide pandemic. Preparing intensive care units (ICU) is an integral part of any pandemic response. In this review, we discuss the key principles and strategies for ICU preparedness. We also describe our initial outbreak measures and share some of the challenges faced. To achieve sustainable ICU services, we propose the need to 1) prepare and implement rapid identification and isolation protocols, and a surge in ICU bed capacity; (2) provide a sustainable workforce with a focus on infection control; (3) ensure adequate supplies to equip ICUs and protect healthcare workers; and (4) maintain quality clinical management, as well as effective communication.","Crit Care","Goh, Ken Junyang","Wong, Jolin","Tien, Jong-Chie Claudia","Ng, Shin Yi","Duu Wen, Sewa","Phua, Ghee Chee","Leong, Carrie Kah-Lai","32393325"],"abstract":["The coronavirus disease 2019 (COVID-19) has rapidly evolved into a worldwide pandemic. Preparing intensive care units (ICU) is an integral part of any pandemic response. In this review, we discuss the key principles and strategies for ICU preparedness. We also describe our initial outbreak measures and share some of the challenges faced. To achieve sustainable ICU services, we propose the need to 1) prepare and implement rapid identification and isolation protocols, and a surge in ICU bed capacity; (2) provide a sustainable workforce with a focus on infection control; (3) ensure adequate supplies to equip ICUs and protect healthcare workers; and (4) maintain quality clinical management, as well as effective communication."],"journal":"Crit Care","authors":["Goh, Ken Junyang","Wong, Jolin","Tien, Jong-Chie Claudia","Ng, Shin Yi","Duu Wen, Sewa","Phua, Ghee Chee","Leong, Carrie Kah-Lai"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32393325","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1186/s13054-020-02916-4","keywords":["coronavirus disease 2019","critical care","infection control","pandemic preparedness","sars-cov-2"],"topics":["Prevention"],"weight":1,"_version_":1666627827874660352,"score":57.062126},{"pmid":32298146,"title":"Hospital Preparedness for COVID-19: A Practical Guide from a Critical Care Perspective.","text":["Hospital Preparedness for COVID-19: A Practical Guide from a Critical Care Perspective.","In response to the estimated potential impact of COVID-19 on New York City hospitals, our institution prepared for an influx of critically ill patients. Multiple areas of surge planning progressed simultaneously focused on infection control, clinical operational challenges, intensive care unit surge capacity, staffing, ethics and maintenance of staff wellness. Protocols developed focused on clinical decisions around intubation, the use of high-flow oxygen, infectious disease consultation and cardiac arrest. Mechanisms to increase bed capacity as well as increase efficiency in intensive care units by outsourcing procedures were implemented. Novel uses of technology to minimize staff exposure to COVID-19, as well as to facilitate family engagement and end of life discussions were encouraged. Education and communication remained key in attempting to standardize care, stay apprized on emerging data as well as to review seminal literature on respiratory failure. Challenges were encountered, and overcome through interdisciplinary collaboration and iterative surge planning as intensive care unit admissions rose. Support was provided for both clinical and nonclinical staff affected by the profound impact COVID-19 had on our city. We describe in granular detail, the procedures and processes developed during a one month period while surge planning was ongoing and the need for intensive care unit capacity rose exponentially. The approaches described provide a potential roadmap for centers that must rapidly adapt to the tremendous challenge introduced by this and potential future pandemics. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).","Am J Respir Crit Care Med","Griffin, Kelly M","Karas, Maria G","Ivascu, Natalia S","Lief, Lindsay","32298146"],"abstract":["In response to the estimated potential impact of COVID-19 on New York City hospitals, our institution prepared for an influx of critically ill patients. Multiple areas of surge planning progressed simultaneously focused on infection control, clinical operational challenges, intensive care unit surge capacity, staffing, ethics and maintenance of staff wellness. Protocols developed focused on clinical decisions around intubation, the use of high-flow oxygen, infectious disease consultation and cardiac arrest. Mechanisms to increase bed capacity as well as increase efficiency in intensive care units by outsourcing procedures were implemented. Novel uses of technology to minimize staff exposure to COVID-19, as well as to facilitate family engagement and end of life discussions were encouraged. Education and communication remained key in attempting to standardize care, stay apprized on emerging data as well as to review seminal literature on respiratory failure. Challenges were encountered, and overcome through interdisciplinary collaboration and iterative surge planning as intensive care unit admissions rose. Support was provided for both clinical and nonclinical staff affected by the profound impact COVID-19 had on our city. We describe in granular detail, the procedures and processes developed during a one month period while surge planning was ongoing and the need for intensive care unit capacity rose exponentially. The approaches described provide a potential roadmap for centers that must rapidly adapt to the tremendous challenge introduced by this and potential future pandemics. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/)."],"journal":"Am J Respir Crit Care Med","authors":["Griffin, Kelly M","Karas, Maria G","Ivascu, Natalia S","Lief, Lindsay"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298146","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1164/rccm.202004-1037CP","keywords":["sars virus","intensive care units","pandemics"],"locations":["New York"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1666138493319905280,"score":49.039288},{"pmid":32458488,"title":"Potential negative effects of the free use of chloroquine to manage COVID-19 in Colombia.","text":["Potential negative effects of the free use of chloroquine to manage COVID-19 in Colombia.","Coronavirus disease 2019 (COVID-19) pandemic has challenged healthcare systems around the world. Unfortunately, failure has ensued: high-income countries have succumbed to the global emergency despite highly prepared human and technological assets. There is no current consensus on pharmacological management of COVID-19, but chloroquine phosphate (CQ) has emerged as a possible therapeutical candidate. However, no conclusive evidence has been published on the efficacy of CQ against SARS-CoV-2 infection. The Colombian government has approved the use of CQ for COVID-19, a measure that could negatively impact a large number of patients who depend on this drug for the treatment of other life-threatening diseases such as malaria and rheumatic autoimmune diseases. Careful consideration should be taken by Colombian authorities regarding the use of CQ in context of the ongoing pandemic. This article is protected by copyright. All rights reserved.","J Med Virol","Teheran, Anibal A","Camero, Gabriel","Hernandez, Carolina","Perez-Garcia, Luis","Guzman, Renato","Paniz-Mondolfi, Alberto","Ramirez, Juan David","32458488"],"abstract":["Coronavirus disease 2019 (COVID-19) pandemic has challenged healthcare systems around the world. Unfortunately, failure has ensued: high-income countries have succumbed to the global emergency despite highly prepared human and technological assets. There is no current consensus on pharmacological management of COVID-19, but chloroquine phosphate (CQ) has emerged as a possible therapeutical candidate. However, no conclusive evidence has been published on the efficacy of CQ against SARS-CoV-2 infection. The Colombian government has approved the use of CQ for COVID-19, a measure that could negatively impact a large number of patients who depend on this drug for the treatment of other life-threatening diseases such as malaria and rheumatic autoimmune diseases. Careful consideration should be taken by Colombian authorities regarding the use of CQ in context of the ongoing pandemic. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Teheran, Anibal A","Camero, Gabriel","Hernandez, Carolina","Perez-Garcia, Luis","Guzman, Renato","Paniz-Mondolfi, Alberto","Ramirez, Juan David"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32458488","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/jmv.26059","keywords":["chloroquine","colombia","coronavirus","covid-19","effect","malaria","negative","pandemic","rheumatic"],"locations":["Colombian","Colombian","Colombia"],"countries":["Colombia"],"countries_codes":["COL|Colombia"],"e_drugs":["Chloroquine","chloroquine diphosphate"],"topics":["Treatment"],"weight":1,"_version_":1668141322658119680,"score":48.147835},{"pmid":32331519,"pmcid":"PMC7180682","title":"Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin.","text":["Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin.","BACKGROUND: COVID-19 pandemics is a challenge for public health and infectious diseases clinicians, especially for the therapeutical approach that is not yet adequately defined. Amid this situation, investigational agents are being used, including chloroquine. We report here the clinical features and therapeutic course of the first reported patient with confirmed COVID-19 pneumonia that recovered in Colombia, after the use of chloroquine and clarithromycin. CASE PRESENTATION: A 34-year-old male, returning from Spain, presented with complaints of fever, and cough, and class-II obesity, being hospitalized. The respiratory viruses and bacteria tested by FilmArray((R)) PCR were negative. Two days later, clarithromycin was started because the patient was suspected as community-acquired pneumonia. At the third day, the rRT-PCR confirmed the SARS-CoV-2 infection. A day later, chloroquine was started because of that. His chest computed tomography was performed and showed bilateral multifocal ground-glass opacities with consolidation, which suggested viral pneumonia as a differential diagnosis. Progressively his clinical condition improved and at day 9, patient rRT-PCR for SARS-CoV-2 became negative. The patient was discharged and isolated at home per 14 days. CONCLUSIONS: Our patient improved significantly. This and other COVID-19 cases are urgently demanding results from clinical trials that support evidence-based therapeutical approaches to this pandemic and the clinical management of patients, especially those at critical care.","Ann Clin Microbiol Antimicrob","Millan-Onate, Jose","Millan, William","Mendoza, Luis Alfonso","Sanchez, Carlos Guillermo","Fernandez-Suarez, Hugo","Bonilla-Aldana, D Katterine","Rodriguez-Morales, Alfonso J","32331519"],"abstract":["BACKGROUND: COVID-19 pandemics is a challenge for public health and infectious diseases clinicians, especially for the therapeutical approach that is not yet adequately defined. Amid this situation, investigational agents are being used, including chloroquine. We report here the clinical features and therapeutic course of the first reported patient with confirmed COVID-19 pneumonia that recovered in Colombia, after the use of chloroquine and clarithromycin. CASE PRESENTATION: A 34-year-old male, returning from Spain, presented with complaints of fever, and cough, and class-II obesity, being hospitalized. The respiratory viruses and bacteria tested by FilmArray((R)) PCR were negative. Two days later, clarithromycin was started because the patient was suspected as community-acquired pneumonia. At the third day, the rRT-PCR confirmed the SARS-CoV-2 infection. A day later, chloroquine was started because of that. His chest computed tomography was performed and showed bilateral multifocal ground-glass opacities with consolidation, which suggested viral pneumonia as a differential diagnosis. Progressively his clinical condition improved and at day 9, patient rRT-PCR for SARS-CoV-2 became negative. The patient was discharged and isolated at home per 14 days. CONCLUSIONS: Our patient improved significantly. This and other COVID-19 cases are urgently demanding results from clinical trials that support evidence-based therapeutical approaches to this pandemic and the clinical management of patients, especially those at critical care."],"journal":"Ann Clin Microbiol Antimicrob","authors":["Millan-Onate, Jose","Millan, William","Mendoza, Luis Alfonso","Sanchez, Carlos Guillermo","Fernandez-Suarez, Hugo","Bonilla-Aldana, D Katterine","Rodriguez-Morales, Alfonso J"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32331519","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1186/s12941-020-00358-y","keywords":["chloroquine","colombia","coronavirus disease 2019 (covid-19)","latin america","severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"],"locations":["Colombia","Spain","Colombia"],"countries":["Colombia","Spain"],"countries_codes":["COL|Colombia","ESP|Spain"],"e_drugs":["Chloroquine","Clarithromycin"],"topics":["Case Report"],"weight":1,"_version_":1666138493966876675,"score":47.536354}]}